Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease

Medicine (United States)

Volumn 96, Issue 11, 2017, Pages

  Zhao, Xiaojing ^a   Zhou, Changcheng ^b   Chen, Han ^a   Ma, Jingjing ^a   Zhu, Yunjuan ^a   Wang, Peixue ^a   Zhang, Yi ^a   Ma, Haiqin ^a   Zhang, Hongjie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Crohn disease; efficacy; low bone mineral density; medical therapy; network meta analysis; safety

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; PHYTOMENADIONE; PLACEBO; RISEDRONIC ACID; SODIUM FLUORIDE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

BAYES THEOREM; BONE DENSITY; COCHRANE LIBRARY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; INCIDENCE; LUMBAR SPINE; MEDLINE; META ANALYSIS; ODDS RATIO; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BONE DISEASES, METABOLIC; COMPLICATION; DRUG EFFECTS; NETWORK META-ANALYSIS; PATHOLOGY;

ALENDRONATE; BAYES THEOREM; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CROHN DISEASE; DIPHOSPHONATES; HUMANS; IMIDAZOLES; NETWORK META-ANALYSIS; RISEDRONATE SODIUM; SODIUM FLUORIDE;

EID: 85015981205     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006378     Document Type: Review

References (52)

1. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44: 653-74.
2. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140: 1785-94.
3. Schulte C, Dignass AU, Mann K, et al. Reduced bonemineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998;4:268-75.
4. Von Tirpitz C, Pischulti G, Klaus J, et al. Pathological bone density in chronic inflammatory bowel diseases-prevalence and risk factors. Z Gastroenterol 1999;37:5-12.
5. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
6. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
7. Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-9.
8. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997;40:313-9.
9. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2011;300:G191-201.
10. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995;10:250-6.
11. Staun M, Tjellesen L, Thale M, et al. Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997;32:226-32.
12. Driscoll RHJr, Meredith SC, Sitrin M, et al. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982;8: 1252-8.
13. Von Tirpitz C, Epp S, Klaus J, et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003;15: 1165-70.
14. Andreassen H, Hylander E, RixM. Gender age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999;94:824-8.
15. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002;51:654-8.
16. Van Bodegraven AA, Bravenboer N, Witte BI, et al. Treatment of bone loss in osteopenic patients with Crohn's disease: A double-blind, randomised trial of oral risedronate 35mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. Gut 2014; 63:1424-30.
17. O'Connor EM, Grealy G, McCarthy J, et al. Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. Br J Nutr 2014;112:1163-74.
18. Soo I, Siffledeen J, Siminoski K, et al. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. J Crohns Colitis 2012;6:777-86.
19. Klaus J, ReinshagenM, Herdt K, et al. Bones and Crohn's: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World J Gastroenterol 2011;7:334-42.
20. Klaus J, Reinshagen M, Herdt K, et al. Intravenous ibandronate or sodium-fluoride-A 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis. J Gastrointestin Liver Dis 2011;20:141-8.
21. Klaus J, Haenle MM, Schröter C, et al. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. Am J Gastroenterol 2011;106:786-93.
22. Sbrocchi AM, Forget S, Laforte D, et al. Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatr Int 2010;52:754-61.
23. Siffledeen JS, Fedorak RN, Siminoski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:122-32.
24. Von Tirpitz C, Klaus J, Steinkamp M, et al. Therapy of osteoporosis in patients with Crohn's disease: A randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Therap 2003;17:807-16.
25. Bartram SA, Peaston RT, Rawlings DJ, et al. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Therap 2003;18:1121-7.
26. Tirpitz C, Klaus J, Brückel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000;12:19-24.
27. Haderslev KV, Tjellesen L, Sorensen HA, et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-46.
28. Melek J, Sakuraba A. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a metaanalysis and systematic review. Clin Gastroenterol Hepatol 2014;12:32. e5-44.e5.
29. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
30. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24: 1-9.
31. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17.
32. Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26: 753-67.
33. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
35. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
36. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med 2003;22:3687-709.
37. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS ONE 2013;8:e76654.
38. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700.
39. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
40. Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.
41. Wang C. Efficacy and safety of zoledronic acid for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Am J Ther 2016;Epub ahead of print.
42. Gu HF, Gu LJ, Wu Y, et al. Efficacy and safety of denosumab in postmenopausal women with osteoporosis: a meta-analysis. Medicine (Baltimore) 2015;94:e1674.
43. Gu JM, Wang L, Lin H, et al. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Acta Pharmacol Sin 2015; 36:841-6.
44. Feng Z, Zeng S, Wang Y, et al. Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis. PLoS One 2013;8:e80890.
45. Amiche MA, Albaum JM, Tadrous M, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporos Int 2016;27:1989-98.
46. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155.
47. Stokkers PC, Deley M, Van Der Spek M, et al. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand J Gastroenterol 2006;41:200-4.
48. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
49. Cosman F. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract 2009;15:483-93.
50. Weycker D,Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-52.
51. Haguenauer D, Welch V, Shea B, et al. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000;11:727-38.
52. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106.